文献速递主动脉疾病

开窗腔内修复用于近肾或肾旁腹主动脉瘤的系统综述

Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: a Systematic Review.
PubMed 文献 · Ann Vasc Surg · 2019-10-17

本系统综述汇总30项研究共23385例患者,其中2271例因近肾或肾旁腹主动脉瘤接受开窗腔内修复(F-EVAR)。汇总早期死亡率为2.55%,技术成功率为96.8%;晚期全因死亡率为17%,1年主要通畅率为94.6%,再干预率为10.4%。结论认为F-EVAR早期安全有效,长期结局可接受但晚期再干预率较高。

要点

  • F-EVAR治疗近肾/肾旁腹主动脉瘤汇总早期死亡率为2.55%,技术成功率达96.8%。
  • 晚期汇总全因死亡率为17%,1年主要通畅率为94.6%,再干预率为10.4%。
  • 长期结局可接受,但晚期再干预率仍较高,需重视术后随访。

核心结论

  • 早期结局表明F-EVAR是近肾/肾旁腹主动脉瘤安全有效的治疗方式。
  • 长期结局可接受,但晚期再干预率仍较高。

研究设计与样本

  • 系统检索Pubmed、Embase、Scopus和Cochrane Library数据库。
  • 纳入报告近肾或肾旁腹主动脉瘤患者F-EVAR后至少早期死亡结局的研究。
  • 共纳入30项研究(17项回顾性、13项前瞻性),总计23385例患者。
  • 其中2271例患者因近肾/肾旁腹主动脉瘤接受F-EVAR治疗。
  • 24项研究提供靶血管数据,共计4216根靶血管待处理。

主要发现

  • 汇总早期死亡率为2.55%(范围0%至6.74%)。
  • 汇总技术成功率为96.8%(范围82.8%至100%)。
  • 晚期汇总全因死亡率为17%(范围0%至50%)。
  • 1年主要通畅率为94.6%(范围91.8%至97.1%)。
  • 再干预率为10.4%(范围0%至57.4%),平均/中位随访时间3至60个月。

关键数值与推荐

  • 30天结局定义为早期,术后30天以后报告的结局定义为晚期。

临床怎么用

  • F-EVAR可用于近肾/肾旁腹主动脉瘤的治疗,早期安全有效。
  • 术后需长期随访监测,因晚期再干预率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This review aims to collect all available data on early and late outcomes in patients undergoing fenestrated endovascular aortic aneurysm repair (F-EVAR) for pararenal or juxtarenal abdominal aortic aneurysms (AAAs). METHODS: The Pubmed, Embase, Scopus and Cochrane Library databases were systematically searched to identify eligible studies. Studies reporting at least early mortality after F-EVAR in patients with pararenal or juxtarenal AAA were included. Thirty-day outcomes were defined as early, and outcomes reported after 30 days postoperatively were defined as late. Basic characteristics of all studies and demographics of patients were reported. RESULTS: Overall, 30 studies (17 retrospective and 13 prospective) including 23,385 patients in total were included. Out of 23,385 patients, a total of 2,271 patients were treated with F-EVAR for pararenal/juxtarenal AAA. Overall, 4,216 target vessels were to be treated (data from 24 studies). Pooled early mortality reached 2.55% (ranging from 0% to 6.74%), with a pooled technical success of 96.8% (ranging from 82.8% to 100%). Regarding late outcomes, pooled all-cause mortality reached 17% (ranging from 0% to 50%), 1-year primary patency was 94.6% (ranging from 91.8% to 97.1%) and reintervention rate was 10.4% (ranging from 0% to 57.4%). Mean/median follow-up ranged from 3 to 60 months. CONCLUSIONS: Early outcomes indicate that F-EVAR is a safe and efficient treatment for patients with pararenal/juxtarenal AAAs. Although long-term outcomes are acceptable, late-intervention rate remains high.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mohamed N, Galyfos G, Anastasiadou C, et al. Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: a Systematic Review. Ann Vasc Surg. 2019. PMID: 31629840. doi:10.1016/j.avsg.2019.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。